Benazepril
An ACE inhibitor prodrug converted to benazeprilat in the body, which blocks the angiotensin-converting enzyme to reduce the production of angiotensin II. Lowering angiotensin II reduces blood pressure and decreases the workload on the heart.
Masse moléculaire
424,5000 g/mol
LogP
1,30
TPSA
95,90 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
InChI
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
Molecular Formula
C24H28N2O5
HBD / HBA
2 / 6
Liaisons Rotatives
10
Atomes Lourds
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
An ACE inhibitor prodrug converted to benazeprilat in the body, which blocks the angiotensin-converting enzyme to reduce the production of angiotensin II. Lowering angiotensin II reduces blood pressure and decreases the workload on the heart.
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Yes, Benazepril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL838. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5362124. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="benazepril"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/benazepril/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/benazepril/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/benazepril/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="benazepril"></drugfyi-drug>